Deferoxamine
Desferal (deferoxamine) is a small molecule pharmaceutical. Deferoxamine was first approved as Desferal on 1982-01-01. It is used to treat bone diseases, corneal diseases, and hemochromatosis in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Desferal (generic drugs available since 2004-03-17)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Deferoxamine mesylate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DESFERAL | Novartis | N-016267 RX | 1982-01-01 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| deferoxamine mesylate | ANDA | 2023-03-01 |
| desferal | New Drug Application | 2020-10-17 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0895 | Injection, deferoxamine mesylate, 500 mg |
Clinical
Clinical Trials
44 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Iron overload | D019190 | — | 6 | 1 | 2 | 2 | 10 | ||
| Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | — | 3 | 2 | 3 | 2 | 9 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | 3 | — | 2 | — | 5 |
| Covid-19 | D000086382 | U07.1 | 1 | 1 | 1 | 1 | — | 3 | |
| Hemosiderosis | D006486 | — | 1 | — | 1 | — | 2 | ||
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemochromatosis | D006432 | EFO_1000642 | E83.11 | — | 2 | 1 | — | — | 3 |
| Oxidative stress | D018384 | EFO_1001905 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thalassemia | D013789 | EFO_1001996 | D56 | 1 | 3 | — | — | 2 | 5 |
| Cerebral hemorrhage | D002543 | 2 | 3 | — | — | — | 4 | ||
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | 2 | 2 | — | — | — | 3 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | 1 | — | — | 1 | 2 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | 2 | — | — | — | 2 |
| Hemolytic anemia | D000743 | D55-D59 | — | 1 | — | — | — | 1 | |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | — | — | — | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | — | — | 1 |
| Diabetic foot | D017719 | EFO_1001459 | — | 1 | — | — | — | 1 | |
| Ischemic stroke | D000083242 | — | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatocellular carcinoma | D006528 | C22.0 | 1 | — | — | — | — | 1 | |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DEFEROXAMINE |
| INN | deferoxamine |
| Description | Deferoxamine (DFOA), also known as desferrioxamine and sold under the brand name Desferal, is a medication that binds iron and aluminium. It is specifically used in iron overdose, hemochromatosis either due to multiple blood transfusions or an underlying genetic condition, and aluminium toxicity in people on dialysis. It is used by injection into a muscle, vein, or under the skin.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN |
Identifiers
| PDB | — |
| CAS-ID | 70-51-9 |
| RxCUI | 3131 |
| ChEMBL ID | CHEMBL556 |
| ChEBI ID | 4356 |
| PubChem CID | 2973 |
| DrugBank | DB00746 |
| UNII ID | J06Y7MXW4D (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 12,425 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,575 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more